Shingles Vaccine Linked‌ to Lower Dementia Rates

Researchers in Wales discovered earlier this year that older individuals who received⁣ the Zostavax vaccine exhibited a 20% reduction in ⁢dementia risk compared to those who did not. This ‍finding, initially reported earlier in 2023, has sparked further inquiry‍ into the potential link between herpes zoster vaccination‍ and cognitive health.

The initial Welsh study prompted further research, and dr.Pascal Geldsetzer of ⁣Stanford University in ​California, a leading‍ researcher in this area, believes ‍the latest findings are notably encouraging. “The most exciting part⁣ (of the latest findings) ‌is⁢ that this really indicates that the herpes zoster vaccine not ‍only has preventive benefits in delaying dementia, but also has therapeutic potential for those who already suffer from that disease,” Dr. Geldsetzer ‌stated in a Stanford News release ⁢ on November 20, 2023.

How Might the Vaccine‍ Work?

The precise mechanism ⁢behind this protective effect⁣ remains unclear.⁣ Researchers are exploring several possibilities, including whether the vaccine broadly activates the immune ⁢system, specifically reduces reactivation of the varicella-zoster virus ⁤(the virus that causes shingles), or operates through an entirely unknown pathway.The researchers emphasize that further study is needed to pinpoint the exact biological processes‍ at play.

Currently, the prevailing theory centers ​on the vaccine’s ability to stimulate a broader immune response.​ ‍ Chronic inflammation is increasingly ⁢recognized as a‍ contributing factor to neurodegenerative diseases like Alzheimer’s disease and other forms of dementia. By⁢ boosting the immune system, the shingles vaccine may help mitigate⁣ this inflammation and protect against cognitive decline.

Shingrix vs. Zostavax: A More Effective Option

While the initial studies focused on Zostavax,the older shingles vaccine,researchers are now investigating whether the newer vaccine,GlaxoSmithKline’s⁣ Shingrix,offers similar or even greater protection against dementia. Zostavax’s effectiveness diminishes over time, and it has largely been replaced by⁢ Shingrix in⁢ many countries.

Shingrix, approved by the U.S. Food and Drug Administration (FDA) in 2017, provides more ​robust and⁤ longer-lasting immunity against shingles. The Centers for ⁢Disease Control and Prevention ‍(CDC) recommends Shingrix for adults 50 years ⁣and older, even if they’ve had shingles or received Zostavax previously.

The superior efficacy of Shingrix is due‍ to its use of a recombinant subunit vaccine and an adjuvant, which enhances the immune response.GlaxoSmithKline data shows Shingrix maintains over 90% effectiveness in preventing shingles ​and its complications for at least four years.

Growing Evidence from Around the Globe

The initial findings from Wales are not isolated. Over the past‍ two years,⁤ researchers have replicated